Pfizer Animal Health’s drug permitted to treat canine cancer

Pfizer Animal Health is proud to be able to launch the first canine cancer treatment approved by the Food and Drug Administration, it has asserted.

The regulatory body has permitted Palladiatm (toceranib phosphate) to be used to manage mast cell tumours in dogs.

Animal caregivers who want to find out what remedy to use for a pet with the disease should consult their vet, who may refer the newly-approved drug.

George Fennell, vice-president of Pfizer Animal Health’s companion animal division, said the company will introduce the treatment to specialists over the coming weeks and months.

“The experience gained during this time will enable us to support veterinarians more effectively when we make the product available for purchase in early 2010,” he explained.

Last month, Pfizer Animal Health was granted approval from the European Commission to market its swine vaccine Improvac across the EU.

Now permitted in 52 countries, it is designed to provide a reduction of boar taint in male pigs to improve the profitability and sustainability of production.